Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
VEGF 165 (human) (rec.)
Product Details | |
---|---|
Synonyms | Vascular Endothelial Growth Factor; VEGF-A; VPF |
Product Type | Protein |
Properties | |
Source/Host | E. coli |
Sequence | Human VEGF 165 (165aa). |
Crossreactivity | Human |
Biological Activity | The ED50 for stimulation of cell proliferation in human umbilical vein endothelial cells by VEGF 165 has been determined to be in the range of 1-5ng/ml. |
MW | ~38.2kDa |
Purity | ≥95% (SDS-PAGE) |
Endotoxin Content | <0.1ng/μg protein. |
Reconstitution | Reconstitute with 50mM acetic acid to a concentration not lower than 50 μg/ml. |
Formulation | Lyophilized. |
Other Product Data | UniProt link P15692-4: VEGF 165 (human) |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. For long term storage we recommend to add at least 0.1% human or bovine serum albumin. |
Use/Stability | Stable for at least 6 months after receipt when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
Human vascular endothelial growth factor (VEGF 165) is produced as a homodimer. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. VEGF 165 is a specific mitogen for vascular endothelial cells and a strong angiogenic factor in vivo. In addition to its action as a mitogen it is a potent vascular permeability factor (VPF) in vivo. It is also a chemoattractant molecule for monocytes and endothelial cells. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels.
Developmental coronary maturation is disturbed by aberrant cardiac vascular endothelial growth factor expression and Notch signalling: N.M.S. van den Akker, et al.; Cardiovasc. Res. 78, 366 (2008)